Related references
Note: Only part of the references are listed.Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma
Julia Furtner et al.
NEURO-ONCOLOGY (2016)
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Martyn E. Caplin et al.
ENDOCRINE-RELATED CANCER (2016)
Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease
Richard Rammo et al.
JOURNAL OF NEUROSURGERY (2016)
Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas
Thomas Graillon et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Andrew D. Norden et al.
NEUROLOGY (2015)
Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy
Marta Simo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
Amira Mohamed et al.
ENDOCRINE-RELATED CANCER (2014)
Comparative study of soft tissue perineurioma and meningioma using a five-marker immunohistochemical panel
Abbas Agaimy et al.
HISTOPATHOLOGY (2014)
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
Thomas Kaley et al.
NEURO-ONCOLOGY (2014)
The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma
Marc C. Chamberlain
CURRENT OPINION IN ONCOLOGY (2012)
Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema
Damoun Nassehi et al.
APMIS (2011)
Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes
A. Durand et al.
CLINICAL NEUROPATHOLOGY (2011)
Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma
Derek R. Johnson et al.
NEURO-ONCOLOGY (2011)
Treatment of unresectable skull base meningiomas with somatostatin analogs
Chris Schulz et al.
NEUROSURGICAL FOCUS (2011)
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function
Chunzhang Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
Marialuisa Appetecchia et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway
Karine Villaume et al.
NEUROENDOCRINOLOGY (2010)
αvβ5/β6 integrin suppression leads to a stimulation of α2β1 dependent cell migration resistant to PI3K/Akt inhibition
Celine Defilles et al.
EXPERIMENTAL CELL RESEARCH (2009)
Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas
Christiaan de Bruin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
Miguel A. Lopez-Lago et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Marianne F. James et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas
Julie Acunzo et al.
CANCER RESEARCH (2008)
Antitumor effects of somatostatin
Stephane Pyronnet et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment
Masamichi Kurosaki et al.
NEUROLOGICAL RESEARCH (2008)
Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients
Eugene A. Woltering et al.
PANCREAS (2008)
Recurrent meningioma - Salvage therapy with long-acting somatostatin analogue
Marc C. Chamberlain et al.
NEUROLOGY (2007)
Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway
Corinne Bousquet et al.
EMBO JOURNAL (2006)
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression
M Theodoropoulou et al.
CANCER RESEARCH (2006)
Simplified method to automatically count bacterial colony forming unit
M Putman et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity
S Arena et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation
G Ferjoux et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
Octreotide Imaging plus bone scintigrams to optimally localize gastroenteropancreatic neuroendocrine tumors
A Le Duc-Pennec et al.
CLINICAL NUCLEAR MEDICINE (2003)
Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells
A Saveanu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Growing vascular endothelial cells express somatostatin subtype 2 receptors
JC Watson et al.
BRITISH JOURNAL OF CANCER (2001)
Occurrence, regulation, and significance of progesterone receptors in human meningioma
MA Blankenstein et al.
STEROIDS (2000)
Share Paper
